Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4993714 | 0.97 | TDP1 (0.68) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL6160608 | 0.89 | KMT2A (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL417403 | 0.88 | KMT2A (0.59) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| Hydrochloric Acid SCHEMBL2002861 | 0.88 | KMT2A (0.57) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL6282770 | 0.87 | KMT2A (0.81) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL913728 | 0.87 | TDP1 (0.69) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL6652699 | 0.87 | TDP1 (0.55) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL10137662 | 0.87 | KMT2A (0.55) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL12642454 | 0.86 | KMT2A (0.68) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL5110705 | 0.85 | PRKCA (0.55) | TDP1KMT2ASLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828548-B2 | Liquid-crystal composition | DIC CORPORATION (JP) | 2017-11-28 | — | — | US | disclosed |
| CN-102754020-B | Liquid crystal aligning agent and liquid crystal display element using the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-03-02 | — | — | CN | disclosed |
| CN-104812805-A | Siloxane compound, modified imide resin, thermosetting resin composition, prepreg, film with resin, laminate, multilayer printed wiring board, and semiconductor package | HITACHI CHEMICAL CO LTD | 2015-07-29 | — | — | CN | disclosed |
| CN-102754020-A | Liquid crystal aligning agent and liquid crystal display element using the same | NISSAN CHEMICAL IND LTD | 2012-10-24 | — | — | CN | disclosed |
| US-20110038805-A1 | COMPOUNDS COMPRISING PARAMAGNETIC CHELATES ARRANGED AROUND A CENTRAL CORE AND THEIR USE IN MAGNETO RESONANCE IMAGING AND SPECTROSCOPY | GE HEALTHCARE AS (NO) | 2011-02-17 | — | — | US | disclosed |
| US-20110038805-A1 | COMPOUNDS COMPRISING PARAMAGNETIC CHELATES ARRANGED AROUND A CENTRAL CORE AND THEIR USE IN MAGNETO RESONANCE IMAGING AND SPECTROSCOPY | GE HEALTHCARE AS (NO) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038805-A1 | COMPOUNDS COMPRISING PARAMAGNETIC CHELATES ARRANGED AROUND A CENTRAL CORE AND THEIR USE IN MAGNETO RESONANCE IMAGING AND SPECTROSCOPY | ABCB7, TSPO, MAG | TDP1 3840/4885KMT2A 2800/4885SLC6A2 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.